Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
Healthcare
$4.40 +0.91%
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
52W Low $2.76High $30.60
Volume 2.01M
Average 1.31M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$369.52M
FY 2025 · Annual
Investing Cash Flow
$287.88M
FY 2025 · Annual
Financing Cash Flow
$2.07M
FY 2025 · Annual
-99.6% YoYCash Flow Statement
USD
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| Deferred Income Tax | 0 | 0 | 0 | (8.56M) |
| Stock-Based Compensation | 5.96M | 8.63M | 19.46M | 43.52M |
| Change in Working Capital | (1.92M) | 12.06M | 14.76M | 26.32M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.29M | (642K) | 8.51M | (6.04M) |
| Other Working Capital | (3.21M) | 12.7M | 6.25M | 32.35M |
| Other Non-Cash Items | (86K) | 3.05M | 1.79M | (190.98M) |
| Operating Cash Flow | (107.72M) | (129.98M) | (255.08M) | (369.52M) |
| Capital Expenditures | (2.41M) | (4.5M) | (1.73M) | (653K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (209.08M) | (11.28M) | (240.06M) | (209.17M) |
| Sales of Investments | 142.73M | 76.25M | 128M | 447.96M |
| Other Investing Activities | 0 | 0 | 0 | 49.74M |
| Investing Cash Flow | (68.75M) | 60.47M | (113.79M) | 287.88M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 193.32M | 2.08M |
| Common Stock Repurchased | 0 | 0 | 0 | (17K) |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.73M | (96K) | 40.59M | 0 |
| Financing Cash Flow | 101.63M | 89.68M | 492.37M | 2.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (74.85M) | 20.18M | 123.5M | (79.58M) |
| Free Cash Flow | (110.13M) | (134.47M) | (256.81M) | (370.18M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$243.3M
+ D&A$3.5M
+ Stock-Based Comp$43.5M
- Deferred Tax-$8.6M
+ Working Capital$26.3M
- Other Non-Cash-$191.0M
= Operating Cash Flow-$369.5M
- Capex-$653.0K
= Free Cash Flow-$370.2M
Analysis
FY2025 free cash flow is -$370.2M. FCF conversion is 152.1% of net income. Operating cash flow was -$369.5M, with capex of -$653.0K. The largest bridge item is Other Non-Cash at -$191.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 |
Does ALMS generate free cash flow?
Alumis Inc. Common Stock (ALMS) generated -$370.18M of free cash flow in fiscal 2025.
How much operating cash flow does ALMS produce?
Operating cash flow was -$369.52M, before capital expenditures of $653,000.00.
Continue the stock analysis
Jump to another research area for this company.